Figure 4From: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes Survival of cetuximab-treated patients by type of KRAS mutation in tumour. Blue line: codon 12 mutations, Red line: codon 13 mutations, Green line: wild-type, Purple line: other KRAS mutations.Back to article page